NVO
Novo Nordisk
DRUG MANUFACTURERS - GENERAL · HEALTHCARE
Novo Nordisk A/S (NVO) is a leading global healthcare company based in Bagsvaerd, Denmark, with a primary focus on diabetes care, obesity management, and hormone replacement therapies. Renowned for its commitment to innovation and research, Novo Nordisk utilizes advanced biotechnology to develop hig...
$43.45
+0.87% (+$0.38)
Volume
6.51M
52W High
$64.16
52W Low
$35.12
Market Cap
$195.75B
What to Watch This Quarter
Based on historical dataConsensus EPS
$0.80
Whisper EPS
$0.82
1.9% above consensus
Last Quarter
$0.96
Current Streak
1 Beat
Avg Surprise (4Q)
+6.17%
Next Earnings Report
Reports in 49 days
Price Chart
EPS History: Consensus vs Actual
Last 12 quartersPrice Movement Around Earnings
Q2 2026
Aug 5, 2026
1-Day:
+3.23%
5-Day:
+7.19%
Q1 2026
May 6, 2026
1-Day:
+0.09%
5-Day:
+1.40%
Q1 2026
May 5, 2026
1-Day:
+1.98%
Q4 2025
Feb 3, 2026
1-Day:
-6.18%
Revenue & Financial Performance
Revenue Whisper
$86.47B
TWN Proprietary Estimate
Last Quarter Revenue
$78.49B
+2.1% YoY
Gross Margin
78.2%
Net Margin: 26.7%
| Quarter | Revenue | YoY Growth | Gross Margin | Op Margin | Net Income |
|---|---|---|---|---|---|
| Q2'26 | $78.49B | +2.1% | 78.2% | 34.5% | $20.99B |
| Q1'26 | $96.82B | +24.0% | 86.0% | 61.6% | $48.56B |
| Q4'25 | $79.14B | -7.6% | 80.9% | 40.1% | $26.89B |
| Q3'25 | $74.98B | +5.1% | 76.1% | 31.6% | $20.01B |
| Q2'25 | $76.86B | +12.9% | 83.3% | 43.5% | $26.50B |
| Q1'25 | $78.09B | +19.5% | 83.5% | 49.7% | $29.03B |
| Q4'24 | $85.68B | +30.1% | 84.8% | 42.9% | $28.23B |
| Q3'24 | $71.31B | +21.4% | 84.1% | 47.4% | $27.30B |
Company Information
Symbol
NVO
Company
Novo Nordisk
Market Cap
$195.75B
Sector
HEALTHCARE
Next Earnings
Nov 4, 2026
Also Reporting Soon
Companies reporting earnings around the same time as NVO
HEALTHCARE Stocks
Other healthcare companies with earnings data
More in DRUG MANUFACTURERS - GENERAL
Compare NVO with competitors
Side-by-side earnings comparison